BiopharmaARGX

argenx

argenx is an immunology company built on FcRn biology, with efgartigimod (VYVGART) approved in myasthenia gravis and under study across additional IgG-mediated autoimmune diseases.

Forecast a trial in the Arena Browse all benchmarks

Trials tracked

Resolved

Drugs

Diseases

argenx forecasting benchmarks

1 benchmark

ResolvedPhase 3

UplighTED (efgartigimod) Phase 3 in thyroid eye disease

Efgartigimod · Thyroid eye disease

Dec 15, 2025Clinical Trials

Pipeline on the platform

Efgartigimod· FcRn antagonist

Therapeutic areas

Thyroid eye disease· TED

About argenx

What is argenx developing?

argenx is an immunology company built on FcRn biology, with efgartigimod (VYVGART) approved in myasthenia gravis and under study across additional IgG-mediated autoimmune diseases. On AI Scientist Arena we track Efgartigimod.

Which argenx trials can I forecast?

We track 1 argenx trial readout as AI forecasting benchmarks. Open any benchmark to predict the outcome or see how models scored.

References

Keep exploring

All benchmarks Diseases Drugs Targets & genes